Construction and characterization of a humanized single chain Fv antibody fragment against the main immunogenic region of the acetylcholine receptor

Journal of Neuroimmunology

Volumn 94, Issue 1-2, 1999, Pages 182-195

  Papanastasiou, Danai ^a   Mamalaki, Avgi ^a   Eliopoulos, Elias ^a   Poulas, Konstantinos ^a   Liolitsas, Christos ^a   Tzartos, Socrates J ^a  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

Author keywords

Acetylcholine receptor; Humanization; Main immunogenic region; Myasthenia gravis; Single chain Fv

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G2A; MONOCLONAL ANTIBODY 198; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; BINDING, COMPETITIVE; DNA PRIMERS; EPITOPES; GENE EXPRESSION; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN VARIABLE REGION; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUSCLE, SKELETAL; MUTAGENESIS; MYASTHENIA GRAVIS; POLYMERASE CHAIN REACTION; PROTEIN STRUCTURE, SECONDARY; RATS; RATS, INBRED LEW; RECEPTORS, CHOLINERGIC; SEQUENCE HOMOLOGY, AMINO ACID; TORPEDO;

EID: 0033081558     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00249-5     Document Type: Article

References (57)

1. Adair J.R. Engineering antibodies for therapy. Immunol. Rev. 130:1992;5-40.
2. Bachelez H., Flageul B., Dudertret L., Fraitag S., Grossman R., Brousse N., Poisson D., Knowles R.W., Wacholtz M.C., Haverty T.P., Chatenoud L., Bach J.F. Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. J. Autoimmun. 11:1998;53-62.
3. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., Rowland A.M., Kotts C., Carver M.E., Shepard H.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA. 89:1992;4285-4289.
4. Changeux, J.P., 1990. Fidia Research Foundation Neuroscience Award Lectures. Raven Press, New York.
5. Chothia C., Novotny J., Bruccoleri R., Karplus M. Domain association in immunoglobulin molecules. The packing of variable domains. J. Mol. Biol. 186:1985;651-663.
6. Chothia C., Lesk A.M., Tramontano A., Levitt M., Smith-Gill S.J., Air G., Sheriff S., Padlan E.A., Davies D., Tulip W.R.et al. Conformations of immunoglobulin hypervariable regions. Nature. 342:1989;877-883.
7. Ciccarelli R.B., Gunyuzlu P., Huang J., Scott C., Oakes F.T. Construction of synthetic genes using PCR after automated DNA synthesis of their entire top and bottom strands. Nucleic Acids Res. 19:1991;6007-6013.
8. Co M.S., Yano S., Hsu R.K., Landolfi N.F., Vasquez M., Cole M., Tso J.T., Bringman T., Laird W., Hudson D.et al. A humanized antibody specific for the platelet integrin gpIIb/IIIa. J. Immunol. 152:1994;2968-2976.
9. Conti-Tronconi B., Tzartos S.J., Lindstrom J. Monoclonal antibodies as probes of acetylcholine receptor structure: II. Binding to native receptor. Biochemistry. 20:1981;2181-2191.
10. Corti A., Barbanti E., Tempest P.R., Carr F.J., Marcucci F. Idiotype-determining regions of a mouse monoclonal antibody and its humanized versions. Identification of framework residues that affect idiotype expression. J. Mol. Biol. 235:1994;53-60.
11. EMBO, 1991. Practical Course: Making Antibodies in Bacteria and on Phages. IRBM, Rome.
12. Evan G.I., Lewis G.K., Ramsay G., Bishop J.M. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol. Cell. Biol. 3:1985;3610-3616.
13. Foote J., Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 224:1992;487-499.
14. Gussow D., Clackson T. Direct clone characterization from plaques and colonies by the polymerase chain reaction. Nucleic Acids Res. 17:1989;4000.
15. Hale G., Dyer M.J., Clark M.R., Phillips J.M., Marcus R., Riechmann L., Winter G., Waldmann H. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet. 2:1988;1394-1399.
16. Heinemann S., Bevan S., Kullberg R., Lindstrom J., Rice J. Modulation of the acetylcholine receptor by anti-receptor antibodies. Proc. Natl. Acad. Sci. USA. 74:1977;3090-3094.
17. Ho S.N., Hunt H.D., Horton R.M., Pullen J.K., Pease L.R. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 77:1989;51-59.
18. Hoogenboom H.R., Griffiths A.D., Johnson K.S., Chiswell D.J., Hudson P., Winter G. Multi-subunit proteins on the surface of filamentous phage methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res. 19:1991;4133-4137.
19. Huston J.S., Levinson D., Mudgett-Hunter M., Tai M.S., Novotny J., Margolies M.N., Ridge R.J., Bruccoleri R.E., Haber E., Crea R., Oppermann H. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA. 85:1988;5879-5883.
20. Jones A.T., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. Sect. A. 47:1991;110-119.
21. Jung S., Pluckthun A. Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting. Protein Eng. 10:1997;959-966.
22. Kabat, E.A., Wu, T.T., Reid-Miller, M., Perry, H.M., Gottesman, K.S., 1987. Sequences of proteins of immunological interest. National Institutes of Health, Bethesda, MD.
23. Klobeck H.G., Combriato G., Zachau H.G. Immunoglobulin genes of the kappa light chain type from two human lymphoid cell lines are closely related. Nucleic Acids Res. 12:1984;6995-7006.
24. Kraoulis P.J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24:1991;946-950.
25. Kudo A., Ishihara T., Nishimura Y., Watanabe T. A cloned human immunoglobulin heavy chain gene with a novel direct-repeat sequence in 5′ flanking region. Gene. 33:1985;181-189.
26. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
27. Lindstrom J., Einarson B., Tzartos S.J. Production and assay of antibodies to acetylcholine receptor. Methods Enzymol. 74:1981;432-460.
28. Lindstrom J., Shelton D., Fugii Y. Myasthenia gravis. Adv. Immunol. 42:1988;233-284.
29. Loutrari H., Kokla A., Tzartos S.J. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur. J. Immunol. 22:1992;2449-2452.
30. Loutrari H., Kokla A., Trakas N., Tzartos S.J. Expression of human-Torpedo hybrid acetylcholine receptor for analysing the subunit specificity of antibodies in sera from patients with myasthenia gravis. Clin. Exp. Immunol. 109:1997;538-546.
31. Luther M.A., Schoepfer R., Whiting P., Casey B., Blatt Y., Montal M.S., Montal M., Lindstrom J. A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671. J. Neurosci. 9:1989;1082-1096.
32. Mamalaki A., Trakas N., Tzartos S.J. Bacterial expression of a single-chain Fv fragment which efficiently protects the acetylcholine receptor against antigenic modulation caused by myasthenic antibodies. Eur. J. Immunol. 23:1993;1839-1845.
33. Mandal G., Kingery B.D., Anchin J.M., Subramaniam S., Linthicum D.S. ABGEN: A knowledge-based automated approach for antibody structure modeling. Nat. Biotechnol. 14:1996;323-328.
34. Maniatis, T., Fritsch, E.F., Sambrook, J., 1982. Molecular Cloning: A Laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
35. Moreland L.W., Haverty T.P., Wacholtz M.C., Knowles R.W., Bucy R.P., Heck L.W.J., Koopman W.J. Non-depleting humanized anti-CD4 monoclonal antibody in patients with refractory rheumatoid arthritis. J. Rheumatol. 25:1998;221-228.
36. Padlan E.A. Anatomy of the antibody molecule. Mol. Immunol. 31:1994;169-217.
37. Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature. 332:1988;323-327.
38. Sato K., Tsuchiya M., Saldanha J., Koishihara Y., Ohsugi Y., Kishimoto T., Bendig M.M. Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions. Mol. Immunol. 31:1994;371-381.
39. Scatchard G. The attractions of proteins for small molecules and ions. Ann. New York Acad. Sci. 51:1949;660-672.
40. Schroff R.W., Foon K.A., Beatty S.M., Oldham R.K., Morgan A.C. Jr. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 45:1985;879-885.
41. Shawler D.L., Bartholomew R.M., Smith L.M., Dillman R.O. Human immune response to multiple injections of murine monoclonal IgG. J. Immunol. 135:1985;1530-1535.
42. Singer I.I., Kawka D.M., DeMartino J.A., Daugherty B.L., Elliston K.O., Alves K., Bush B.L., Cameron P.M., Cuca G.C., Davies P.et al. Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences. J. Immunol. 150:1993;2844-2857.
43. Sophianos D., Tzartos S.J. Fab fragments of monoclonal antibodies protect the human acetylcholine receptor against degradation caused by myasthenic sera. J. Autoimmun. 2:1989;777-789.
44. Stratton M.R., Darling J., Pilkington G.J., Lantos P.L., Reeves B.R., Cooper C.S. Characterisation of the human cell line TE671. Carcinogenesis. 10:1989;899-905.
45. Tramontano A., Chothia C., Lesk A.M. Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. J. Mol. Biol. 215:1990;175-182.
46. Tzartos S.J., Lindstrom J.L. Monoclonal antibodies to probe acetylcholine receptor structure: localization of the MIR and detection of similarities between subunits. Proc. Natl. Acad. Sci. USA. 77:1980;755-759.
47. Tzartos S.J., Rand D.E., Einarson B.E., Lindstrom J.M. Mapping of surface structures of Electrophorus acetylcholine receptor using monoclonal antibodies. J. Biol. Chem. 256:1981;8635-8645.
48. Tzartos S.J., Langeberg L., Hochschwender S., Lindstrom J. Demonstration of a main immunogenic region on acetylcholine receptors from human muscle using monoclonal antibodies to human receptor. FEBS Lett. 158:1983;116-118.
49. Tzartos S.J., Sophianos D., Efthimiadis A. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera. J. Immunol. 134:1985;2343-2349.
50. Tzartos S.J., Langeberg L., Hochschwender S., Swanson L., Lindstrom J. Characteristics of monoclonal antibodies to denatured Torpedo and to native calf acetylcholine receptors: species, subunit and region specificity. J. Neuroimmunol. 10:1986;235-253.
51. Tzartos S.J., Hochschwender S., Vasquez P., Lindstrom J. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J. Neuroimmunol. 15:1987;185-194.
52. Tzartos S.J., Barkas T., Cung M.T., Mamalaki A., Marraud M., Orlewski P., Papanastasiou D., Sakarellos C., Sakarellos Daitsiotis M., Tsantili P., Tsikaris V. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol. Rev. 163:1998;89-120.
53. Unwin N. Neurotransmitter action: opening of ligand-gated ion channels. Cell. 72(Suppl.):1993;31-41.
54. Vatzaki E.H., Acharya K.R., Oikonomakos N.G., Tzartos S.J. Crystallization and preliminary crystallographic study of an Fab fragment of a pathogenic rat monoclonal antibody against the nicotinic acetylcholine receptor. Protein Sci. 2:1993;1770-1772.
55. Vaughan T.J., Williams A.J., Pritchard K., Osbourn J.K., Pope A.R., Earnshaw J.C., McCafferty J., Hodits R.A., Wilton J., Johnson K.S. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol. 14:1996;309-314.
56. Ward E.S., Gussow D., Griffiths A.D., Jones P.T., Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature. 341:1989;544-546.
57. Xiang J., Sha Y., Jia Z., Prasad L., Delbaere L.T. Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops. J. Mol. Biol. 253:1995;385-390.